abiraterone has been researched along with pindolol in 1 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (pindolol) | Trials (pindolol) | Recent Studies (post-2010) (pindolol) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 3,718 | 662 | 92 |
| Protein | Taxonomy | abiraterone (IC50) | pindolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.0005 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.0009 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 0.088 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.048 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.048 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for abiraterone and pindolol
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |